121 related articles for article (PubMed ID: 16282507)
1. Multifocal angiostatic therapy: an update.
McCarty MF; Block KI
Integr Cancer Ther; 2005 Dec; 4(4):301-14. PubMed ID: 16282507
[TBL] [Abstract][Full Text] [Related]
2. A wholly nutritional 'multifocal angiostatic therapy' for control of disseminated cancer.
McCarty MF
Med Hypotheses; 2003 Jul; 61(1):1-15. PubMed ID: 12781633
[TBL] [Abstract][Full Text] [Related]
3. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
McCarty MF
Integr Cancer Ther; 2004 Dec; 3(4):349-80. PubMed ID: 15523106
[TBL] [Abstract][Full Text] [Related]
4. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
5. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
Pan Q; Kleer CG; van Golen KL; Irani J; Bottema KM; Bias C; De Carvalho M; Mesri EA; Robins DM; Dick RD; Brewer GJ; Merajver SD
Cancer Res; 2002 Sep; 62(17):4854-9. PubMed ID: 12208730
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
7. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Ischenko I; Guba M; Yezhelyev M; Papyan A; Schmid G; Green T; Fennell M; Jauch KW; Bruns CJ
Angiogenesis; 2007; 10(3):167-82. PubMed ID: 17486419
[TBL] [Abstract][Full Text] [Related]
8. Toward a core nutraceutical program for cancer management.
McCarty MF; Block KI
Integr Cancer Ther; 2006 Jun; 5(2):150-71. PubMed ID: 16685077
[TBL] [Abstract][Full Text] [Related]
9. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol.
Shibata A; Nakagawa K; Sookwong P; Tsuzuki T; Oikawa S; Miyazawa T
Biochem Pharmacol; 2008 Aug; 76(3):330-9. PubMed ID: 18599020
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic function of tocotrienol.
Miyazawa T; Shibata A; Nakagawa K; Tsuzuki T
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():253-6. PubMed ID: 18296349
[TBL] [Abstract][Full Text] [Related]
11. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
13. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
Kong D; Okamura M; Yoshimi H; Yamori T
Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
[TBL] [Abstract][Full Text] [Related]
15. Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
Nicoli S; Ribatti D; Cotelli F; Presta M
Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396
[TBL] [Abstract][Full Text] [Related]
16. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
17. Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy.
McCarty MF; Block KI
Integr Cancer Ther; 2006 Sep; 5(3):252-68. PubMed ID: 16880431
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf.
Kalkunte S; Brard L; Granai CO; Swamy N
Angiogenesis; 2005; 8(4):349-60. PubMed ID: 16400520
[TBL] [Abstract][Full Text] [Related]
19. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Jung MH; Lee SH; Ahn EM; Lee YM
Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
[TBL] [Abstract][Full Text] [Related]
20. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Diagaradjane P; Guha S; Deorukhkar A; Shentu S; Aggarwal BB; Krishnan S
Clin Cancer Res; 2008 Apr; 14(7):2128-36. PubMed ID: 18381954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
